ConjuChem Announces New President and CEO
News Oct 14, 2005
ConjuChem Inc. has announced the appointment of Mark D. Perrin as president and CEO, effective October 17th 2005. Outgoing president and interim CEO Jacques Lapointe will remain as executive chairman.
“Mark's substantial operating experience will enable him to guide ConjuChem through its next phase of growth,” said Jacques Lapointe.
“As incoming president and CEO, his priority will be to focus the company around the delivery of key clinical and commercial milestones.”
“His appointment reinforces ConjuChem's commitment to building long-term value for our shareholders."
Mr. Perrin's professional achievements to date are substantial. As the Executive Vice President and Chief Commercial Officer at Orphan Medical, he was responsible for all business development, marketing and sales activities.
Previously, as Executive Vice President of Commercial Operations at COR Therapeutics, he played the lead role in establishing the company's commercial infrastructure.
Prior to that, Mr. Perrin held progressively senior management roles in the pharmaceutical industry including Division Manager, Lederle Canada, Vice President & General Manager, Lederle Laboratories (U.S.) and Vice President, Marketing and Sales for the U.S. at Burroughs Wellcome.
“The fundamental science behind ConjuChem and the inherent value proposition that it offers to the drug development community - long-lasting safe compounds – are compelling. They represent the kind of innovation that is in high demand,” said Mark Perrin.
“My entire professional career has focused on leadership and commercial operations in the pharmaceutical space.”
“I intend to bring this skill set and passion to ConjuChem as we translate this exciting science into tangible, commercial fundamentals.”
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE